99 related articles for article (PubMed ID: 27638857)
1. Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib.
Eigenmann MJ; Frances N; Hoffmann G; Lavé T; Walz AC
Mol Cancer Ther; 2016 Dec; 15(12):3110-3119. PubMed ID: 27638857
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Wang S; Guo P; Wang X; Zhou Q; Gallo JM
Mol Cancer Ther; 2008 Feb; 7(2):407-17. PubMed ID: 18281523
[TBL] [Abstract][Full Text] [Related]
4. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
[TBL] [Abstract][Full Text] [Related]
5. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Jovelet C; Seck A; Mir O; Simasotchi C; Broutin S; Goffinet F; Bidart JM; Paci A; Gil S
Ann Oncol; 2015 Jul; 26(7):1500-4. PubMed ID: 25851627
[TBL] [Abstract][Full Text] [Related]
6. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Moltó J; Rajoli R; Back D; Valle M; Miranda C; Owen A; Clotet B; Siccardi M
J Antimicrob Chemother; 2017 Mar; 72(3):805-811. PubMed ID: 27999009
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.
Wang S; Zhou Q; Gallo JM
Mol Cancer Ther; 2009 Jun; 8(6):1438-47. PubMed ID: 19509243
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
9. PKPD modeling of acquired resistance to anti-cancer drug treatment.
Eigenmann MJ; Frances N; Lavé T; Walz AC
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):617-630. PubMed ID: 29090407
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Yu-Hua Z; Liang S; Bin L; Guo-Qiang LI
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2016 Jun; 32(6):525-528. PubMed ID: 29926620
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
12. Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats.
Yasumuro O; Uchida S; Kashiwagura Y; Suzuki A; Tanaka S; Inui N; Watanabe H; Namiki N
Xenobiotica; 2018 Nov; 48(11):1106-1112. PubMed ID: 29057719
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
Trummer BJ; Iyer V; Balu-Iyer SV; O'Connor R; Straubinger RM
J Pharm Sci; 2012 Aug; 101(8):2763-76. PubMed ID: 22581704
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Passaro A; Alesini D; Pochesci A; Cortesi E
Anticancer Agents Med Chem; 2014 Jun; 14(5):646-50. PubMed ID: 23140355
[TBL] [Abstract][Full Text] [Related]
15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
16. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
18. Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer.
Grüner BM; Winkelmann I; Feuchtinger A; Sun N; Balluff B; Teichmann N; Herner A; Kalideris E; Steiger K; Braren R; Aichler M; Esposito I; Schmid RM; Walch A; Siveke JT
Mol Cancer Ther; 2016 May; 15(5):1145-52. PubMed ID: 26823494
[TBL] [Abstract][Full Text] [Related]
19. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
